Literature DB >> 20455400

[In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].

Burçe Yalçin1, Ayşe Kalkanci, Feryal Gürelik, Işil Fidan, Semra Kustimur, Sengül Ozdek.   

Abstract

Contradictory results such as synergy or indifferent effect, have been reported about the interactions between quinolones and antifungal drugs in different studies. The aim of this study was to investigate the in vitro susceptibilities of Candida spp. to moxifloxacin (MOX) alone and MOX + amphotericin B (AmB) combination. A total of 20 strains were included to the study, of which 19 were clinical isolates (10 Candida albicans, 4 Candida glabrata, 2 Candida parapsilosis, 1 Candida tropicalis, 1 Candida pelliculosa ve 1 Candida sake) and 1 was a standard strain (C. albicans ATCC 90028). In vitro susceptibilities of the strains to MOX with AmB were investigated by broth microdilution method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI), and in vitro interaction of these drugs were determined by a chequerboard titration method. Minimal inhibitory concentration (MIC) values of Candida spp. for MOX were found > or = 400 microg/ml indicating that MOX, by itself has no antifungal activity. AmB MIC values were found 1 microg/ml in 11 of the clinical isolates, and < or = 0.5 microg/ml in the other 8 clinical isolates and 1 standard strain. The inhibitor activity of AmB was slightly enhanced when combined with MOX, there being a decrease of 1-4 fold dilutions in the AmB MICs against all isolates tested. Synergistic effect between MOX and AmB, defined as a fractional inhibitory concentration (FIC) index as < or = 0.5, was observed in 90% (18/20; all were clinical isolates) of the strains, whereas indifferent effect (FIC = 1) was detected in 10% (2/20; 1 was clinical and 1 was standard strain) of the strains. Antagonistic effect was not observed for this combination even at 48th hours. It was concluded that these preliminary results should be confirmed by large-scaled in vitro and in vivo studies to evaluate MOX + AmB combination as a therapeutic option for the treatment of Candida infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455400

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  3 in total

Review 1.  Topoisomerase II as a target for repurposed antibiotics in Candida albicans: an in silico study.

Authors:  Ashwini Khanderao Jadhav; Sankunny Mohan Karuppayil
Journal:  In Silico Pharmacol       Date:  2021-03-26

2.  Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals against Candida and Aspergillus spp.

Authors:  Anne Tøndervik; Håvard Sletta; Geir Klinkenberg; Charlotte Emanuel; Lydia C Powell; Manon F Pritchard; Saira Khan; Kieron M Craine; Edvar Onsøyen; Phil D Rye; Chris Wright; David W Thomas; Katja E Hill
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 3.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.